Numazu City, Shizuoka, Japan - March 17, 2011 - CanBas Co., Ltd. announces the presentation of abstracts on an additional mechanism of action of its Phase II clinical candidate CBP501 and the novel CRM1 inhibitor CBS9106 at the Annual Meeting of the American Association for Cancer Research (AACR), to be held in Orlando, FL, on April 2 - April 6, 2011.
Presentation Schedule:
Abstract Number: 658
Presentation Title: CBS9106 is a novel low toxic reversible oral CRM1 inhibitor with CRM1 degrading activity
Presentation Time: Sunday, April 3, 2011, 1:00 PM - 5:00 PM
Location: Exhibit Hall A4-C, Poster Section 28
Abstract Number: 2635
Presentation Title: CBP501-calmodulin binding contributes to sensitizing tumor cells to CDDP and BLM
Presentation Time: Monday, April 4, 2011, 1:00 PM - 5:00 PM
Location: Exhibit Hall A4-C, Poster Section 30
About CBP501 and CBS9106
CBP501 is a synthetic peptide discovered using CanBas’ proprietary phenotypic screen for G2 abrogation activity. CBP501 reduces phosphorylation of CDC25C on Ser216 and increases intracellular concentration of cisplatin. Randomized Phase II studies are ongoing in the US and other countries for first-line treatment of late stage malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). CBS9106 is a preclinical stage, synthetic small molecule that demonstrates cancer cell-specific cytotoxicity, both alone and in synergy with certain DNA-damaging treatments, acting through inhibition and destabilization of CRM1.
About CanBas
CanBas is a publicly listed (Tokyo Stock Exchange: M-4575), clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology drugs targeting the cell cycle. CanBas has developed a proprietary phenotypic screening platform, which has been used to identify a pipeline of novel oncology drug candidates, including CBP501 and CBS9106.
Source: CanBas Co., Ltd.
Contacts:
Takumi Kawabe, CEO CanBas Co., Ltd. Cbp501@canbas.co.jp
Vivian Lee Aqua Partners LLC vlee@aquapartners.net
Website: http://www.canbas.co.jp/eng/index.html
